Secondary analysis
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
- Secondary analysis of the TRANSFORM-HF randomised trial
- open-label
- pragmatic
- 60 US hospitals
- prespecified secondary end points
Baseline data available for 2787 (97.5%) patients for Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and 2624 (91.8%) for PHQ-2
Authors' conclusion
Among patients discharged after hospitalization for HF, a strategy of torsemide compared with furosemide did not improve symptoms or quality of life over 12 months.
Study context
- Population
- Patients hospitalized for heart failure (HF) regardless of EF
- Participants
- 2,859 patients
- Comparison
- Torsemide vs furosemide
- Primary endpoint
- Change from baseline in KCCQ-CSS (adjusted MD; clinically important difference ≥5 points) and Patient Health Questionnaire-2 score ≥3 (prespecified secondary end points)
- Follow-up
- 12 months
Primary result
KCCQ-CSS change and PHQ-2 score ≥3
Adjusted mean difference
0.06
95% CI −2.26 to 2.37
P = 0.96
By group
As reported in the abstract
Secondary outcomes
Change in KCCQ-CSS from baseline · 1 month
- Adjusted MD 1.36 (95% CI, −0.64 to 3.36), similar between groups
- P = 0.18
Change in KCCQ-CSS from baseline · 6 months
- Adjusted MD −0.37 (95% CI, −2.52 to 1.78), similar between groups
- P = 0.73
Change in KCCQ-CSS by EF phenotype, NYHA class at randomization and pre-hospitalization loop diuretic (subgroups)
- Results similar across subgroups
Change in KCCQ-CSS, all-cause mortality, all-cause hospitalization by baseline KCCQ-CSS tertile (subgroups)
- No significant difference between torsemide and furosemide irrespective of baseline tertile
Original publication
Summarised from the published abstract; every number is checked against it